Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Treatment compliance is a key success factor in obtaining the full benefit of Pegetron
(peginterferon alfa-2b [PegIFN-2b] plus ribavirin combination) therapy for patients.
Treatment-naïve patients with chronic hepatitis C (CHC) in Canada to whom Pegetron Redipen
was prescribed will receive Pegetron Redipen therapy in accordance with approved labeling.
The study will assess the effect of the newly approved Pegetron Redipen on treatment
compliance and its effect on sustained virologic response rates. Sustained virologic response
is defined as negative hepatitis C virus ribonucleic acid (HCV-RNA) six months
post-treatment.